7/28/2009

The FDA deferred its approval decision on extended-release Intuniv, Shire's drug candidate for attention-deficit/hyperactivity disorder, because of unresolved labeling discussions. Shire said the company remains confident that the treatment will be approved in the fourth quarter.

Full Story:
Reuters

Related Summaries